Science Media Centre16m
expert reaction to news that the FDA has approved the drug Cobenfy (KarXT) for schizophrenia
Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, ...
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...
Alembic Pharma gets USFDA nod for generic drug used to treat schizophrenia
Paliperidone extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg have an estimated market size of $48 million for 12 ...
Investor's Business Daily on MSN34m
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...
FDA Approves New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 (HealthDay News) -- The first new type of medication in decades to help fight against schizophrenia ...
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...
Alembic Pharma secures FDA approval for Schizophrenia treatment, stocks in red
Alembic Pharmaceuticals receives FDA approval for Paliperidone Tablets, trading at ₹1,179.95 on NSE, expanding its global ...
money.rediff50m
Alembic Pharma Gets USFDA Nod for Generic Schizophrenia Drug
Alembic Pharmaceuticals receives USFDA approval for its generic version of Paliperidone extended-release tablets, indicated ...
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...